



# Unique and Common Features of Innate-Like Human V $\delta$ 2<sup>+</sup> $\gamma$ $\delta$ T Cells and Mucosal-Associated Invariant T Cells

Nicholas M. Provine<sup>1\*†</sup>, Benedikt Binder<sup>2†</sup>, Michael E. B. FitzPatrick<sup>1†</sup>, Anita Schuch<sup>2,3</sup>, Lucy C. Garner<sup>1</sup>, Kate D. Williamson<sup>1</sup>, Bonnie van Wilgenburg<sup>4</sup>, Robert Thimme<sup>2</sup>, Paul Klenerman<sup>1,4</sup> and Maïke Hofmann<sup>2\*</sup>

<sup>1</sup>Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,

<sup>2</sup>Department of Internal Medicine II, University Hospital Freiburg, Freiburg, Germany, <sup>3</sup>Faculty of Biology, University of

Freiburg, Freiburg, Germany, <sup>4</sup>Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom

## OPEN ACCESS

### Edited by:

Yun-Cai Liu,  
Tsinghua University, China

### Reviewed by:

Karin Schilbach,  
Universität Tübingen, Germany  
Tom Taghon,  
Ghent University, Belgium

### \*Correspondence:

Nicholas M. Provine  
nicholas.provine@ndm.ox.ac.uk;  
Maïke Hofmann  
maïke.hofmann@uniklinik-freiburg.de

<sup>†</sup>These authors have contributed  
equally to this work.

### Specialty section:

This article was submitted to  
T Cell Biology,  
a section of the journal  
Frontiers in Immunology

**Received:** 23 January 2018

**Accepted:** 27 March 2018

**Published:** 23 April 2018

### Citation:

Provine NM, Binder B,  
FitzPatrick MEB, Schuch A,  
Garner LC, Williamson KD,  
van Wilgenburg B, Thimme R,  
Klenerman P and Hofmann M (2018)  
Unique and Common Features  
of Innate-Like Human V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T  
Cells and Mucosal-Associated  
Invariant T Cells.  
*Front. Immunol.* 9:756.  
doi: 10.3389/fimmu.2018.00756

Mucosal-associated invariant T (MAIT) cells are innate-like T cells abundant in humans that can be activated in a TCR-independent manner by inflammatory and antiviral cytokines. In humans, the capacity for TCR-independent activation is functionally linked to a transcriptional program that can be identified by the expression of the C-type lectin receptor, CD161. In addition to MAIT cells, it has been demonstrated that a subset of  $\gamma$  $\delta$ T cells expresses CD161 and can be activated by TCR-independent cytokine stimulation. In this study, we sought to clarify the nature of cytokine-responsive human  $\gamma$  $\delta$ T cells. We could link CD161 expression on V $\delta$ 2<sup>+</sup> versus V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cells to the observation that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells, but not V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cells, robustly produced IFN- $\gamma$  upon stimulation with a variety of cytokine combinations. Interestingly, both CD161<sup>+</sup> and CD161<sup>-</sup> V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells responded to these stimuli, with increased functionality within the CD161<sup>+</sup> subset. This innate-like responsiveness corresponded to high expression of PLZF and IL-18R $\alpha$ , analogous to MAIT cells. V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells in human duodenum and liver maintained a CD161<sup>+</sup> IL-18R $\alpha$ <sup>+</sup> phenotype and produced IFN- $\gamma$  in response to IL-12 and IL-18 stimulation. In contrast to MAIT cells, we could not detect IL-17A production but observed higher steady-state expression of Granzyme B by V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells. Finally, we investigated the frequency and functionality of  $\gamma$  $\delta$ T cells in the context of chronic hepatitis C virus infection, as MAIT cells are reduced in frequency in this disease. By contrast, V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells were maintained in frequency and displayed unimpaired IFN- $\gamma$  production in response to cytokine stimulation. In sum, human V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are a functionally distinct population of cytokine-responsive innate-like T cells that is abundant in blood and tissues with similarities to human MAIT cells.

**Keywords:** mucosal-associated invariant T,  $\gamma$  $\delta$  T cells, innate-like T cells, hepatitis C virus, mucosal immunology, V $\delta$ 2  $\gamma$  $\delta$  T cells

## INTRODUCTION

The capacity of human T cells to be activated independent of TCR ligation is atypical and largely restricted to specific, defined innate-like T cell subsets, of which the mucosal-associated invariant T (MAIT) cell population is the most abundant in humans (1). A fundamental innate-like characteristic of MAIT cells is that they can be stimulated to produce IFN- $\gamma$  by cytokines in the absence of exogenous TCR ligand (2). Cytokine-mediated induction of IFN- $\gamma$  by T cells requires combinatorial stimulation

with at least two cytokines, and a number of cytokines have been shown to be effective in this regard (3, 4). IL-12 combined with either IL-15 or IL-18 is the most potent cytokine stimulus identified. The exact *in vivo* implications of the capacity for these cells to be activated by TCR-independent stimuli remains unclear, but it has been shown to augment activation by TCR ligation and allow for the activation of MAIT cells by pathogens that do not produce the relevant TCR ligands (3, 5–7).

Intriguingly, in humans, this capacity for TCR-independent, cytokine-mediated IFN- $\gamma$  production is also seen to varying degrees in conventional CD8<sup>+</sup>  $\alpha$  $\beta$ T cells, CD4<sup>+</sup>  $\alpha$  $\beta$ T cells, and  $\gamma$  $\delta$ T cells. Across all populations, a shared transcriptional signature is expressed by the IFN- $\gamma$ -producing, cytokine-responsive subset and this signature can be identified by the expression of CD161, of which MAIT cells express the highest levels (8). While only a subset of conventional CD4<sup>+</sup> and CD8<sup>+</sup>  $\alpha$  $\beta$ T cells expresses CD161, a large fraction of  $\gamma$  $\delta$ T cells express CD161, and these cells respond more robustly to cytokine stimuli than conventional  $\alpha$  $\beta$ T cells. Thus, we sought to more thoroughly characterize the cytokine-responsive subset of  $\gamma$  $\delta$ T cells.

In human circulation, two major subsets of  $\gamma$  $\delta$ T cells can be identified and differentiated based on the expression of a TCR utilizing either V $\delta$ 1 or V $\delta$ 2 gene segments, hereafter V $\delta$ 1<sup>+</sup> or V $\delta$ 2<sup>+</sup>, respectively (9). Recent work has demonstrated that the circulating V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cell population shares several characteristics with conventional  $\alpha$  $\beta$ T cells, with regard to high levels of clonal TCR diversity, a large pool of phenotypically naïve cells, and a small subset of clonally expanded memory cells (10). By contrast, circulating V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells display many characteristics more in line with the MAIT cell population, including limited TCR sequence diversity, with up to 95% of TCRs being comprised of a V $\delta$ 2/V $\gamma$ 9 pairing (11, 12). It has been demonstrated that  $\gamma$  $\delta$ T cells, including the V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell subset, can be activated through a cytokine-dependent, TCR-independent stimulation process (13, 14). This is highly analogous to what has been recently reported for MAIT cells (3, 6). In total, it appears that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells share several of the innate-like T cell characteristics seen in MAIT cells.

We thus hypothesized that the previously identified CD161<sup>+</sup>  $\gamma$  $\delta$ T cells and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are in fact one and the same cell population, and represent an additional, abundant population of innate-like T cells. Consistent with this, we demonstrate that the majority of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells express CD161, thus linking the two prior reports of cytokine-responsive human  $\gamma$  $\delta$ T cells (8, 13). Extending these findings, we demonstrate that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are present at frequencies similar to MAIT cells in liver and duodenum and maintain an innate-like phenotype and responsiveness to cytokine stimulation. However, in contrast to MAIT cells, V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells did not exhibit type 17 effector functionality. Collectively, these data demonstrate that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cells are both abundant innate-like T cell populations that share several functional characteristics. Interestingly, we could detect preserved frequency and phenotype of V $\delta$ 2<sup>+</sup> T cells in patients chronically infected with hepatitis C virus (HCV), in contrast to the known reduction in MAIT cell frequency. These data stress the importance of including studies of the V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell population when investigating cytokine-mediated activation of lymphocyte populations.

## MATERIALS AND METHODS

### Blood Sample Processing

Peripheral blood mononuclear cells (PBMCs) were isolated from fresh human blood by density gradient centrifugation. Briefly, blood was diluted in PBS and layered over Lymphoprep (Axis-Shield) or Pancoll (PAN Biotech). Samples were centrifuged at 973 g for 30 min without brake. The mononuclear cell layer was collected and washed in R10 [RPMI-1640 (Lonza) supplemented with 10% FBS (Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-Aldrich)]. Residual red blood cells were lysed by incubation in 1 $\times$  ACK (Ammonium-Chloride-Potassium) lysis solution for <5 min. Cells were washed an additional time in R10 before downstream utilization or storage in liquid nitrogen for subsequent use.

### Tissue Sample Processing

Liver samples were collected from the healthy margin of patients undergoing tissue resection for metastases of colorectal cancer or hepatocellular carcinoma. Tissue was dissociated by grinding through a 70  $\mu$ m filter (ThermoFisher). Duodenal samples were collected by biopsy during endoscopy for routine clinical indications. Duodenal biopsies were incubated for 1 h shaking at 37°C in a solution of R10 + 1 mg/ml Collagenase D (Sigma-Aldrich) + 100  $\mu$ g/ml DNase I (ThermoFisher). Biopsies were then dissociated by vigorous agitation using a GentleMACS Dissociator (Miltenyi Biotec) and strained through a 70  $\mu$ m filter. From this point, liver and duodenal samples were processed in the same way. Samples were washed once in R10 media. Mononuclear cells were isolated on a discontinuous 70–35% Percoll gradient (GE Healthcare) by centrifugation at 700 g for 20 min without brake. The interface containing mononuclear cells was collected and washed in R10. Residual red blood cells were lysed using 1 $\times$  ACK lysis solution and cells were washed two additional times with R10. Tissue-derived cells were used immediately for subsequent experiments.

### Study Cohort

Thirty-three chronically HCV-infected patients were recruited at the Department of Medicine II of the University Hospital Freiburg, Germany. Viral loads and transaminases of patients were determined as part of the clinical diagnostics at the University Hospital Freiburg. Patients with liver cirrhosis were excluded from the study. At the time of the study none of the patients chronically infected with HCV were receiving current antiviral treatment. Patient characteristics are listed in **Table 1**. Healthy controls were collected from the John Radcliffe Hospital, Oxford University Hospitals or recruited at the Department of Medicine II of the University of Freiburg Hospital.

### In Vitro Stimulation

*In vitro* stimulation was performed as previously described (2). Briefly, purified single cell suspensions of blood-, liver-, and duodenum-derived mononuclear cells were plated at 10<sup>6</sup> cells per well of a 96-well U-bottom plate. IL-12 (R&D Systems), IL-15 (R&D Systems), IL-18 (R&D Systems), or IFN- $\beta$  (Sigma) were

added at a final concentration of 50 ng/ml. Cells were incubated for 16 h at 37°C, 5% CO<sub>2</sub>. After 16 h, Brefeldin A (5  $\mu$ g/ml final concentration), and Monensin (2  $\mu$ M final concentration) were added and incubation was carried out for an additional 4 h. After 20 h of total stimulation, intracellular cytokine staining was performed as described below. For PMA (phorbol 12-myristate 13-acetate) and ionomycin stimulation, Cell Activation Cocktail

(BioLegend) was used per the manufacturer's instructions in the presence of Brefeldin A and Monensin, and cells were incubated for 4 h at 37°C, 5% CO<sub>2</sub>.

## Flow Cytometry

For surface markers, cells were stained in a 50  $\mu$ l volume of FACS buffer (PBS + 0.05% BSA + 1% penicillin/streptomycin) for 30 min at 4°C. Surface antibodies were: CD3 (clones OKT3 or UCHT1), V $\delta$ 1 (clone REA173), V $\delta$ 2 (clone B6), V $\alpha$ 7.2 (clone 3C10), CD161 (clone 191B8), IL-18R $\alpha$  (clone H44 or 70625), CCR6 (clone G034E3), and fixable viability dye (ThermoFisher). Specifically for CCR6, staining was performed at 37°C for 30 min. Cells were washed once in FACS buffer and then standard surface staining was performed. For intracellular cytokine staining, surface staining was performed, as above, and then cells were fixed and permeabilized by 20 min incubation at 4°C in Cytofix/Cytoperm (BD Biosciences). Cells were washed twice in BD Perm/Wash Buffer (BD Biosciences). Intracellular staining for Granzyme B (clone GB11), IFN- $\gamma$  (clone B27), and IL-17A (clone BL168) was performed in a 50  $\mu$ l volume of BD Perm/Wash Buffer for 30 min at 4°C. For transcription factor staining, staining of surface markers was performed, as above, and then cells were fixed for 1 h at room temperature using FoxP3 Fixation Buffer (ThermoFisher). Cells were washed in FoxP3 kit Wash Buffer, and permeabilized for 1 h at room temperature in FoxP3 kit Wash Buffer. PLZF (clone R17-809) and ROR $\gamma$ t (clone Q21-559) transcription factors were stained in a 50  $\mu$ l volume of FoxP3 kit Wash Buffer for 1 h at room temperature. Following staining, cells were stored at 4°C until data acquisition. All antibodies were purchased from BD Biosciences, BioLegend, Miltenyi Biotec, or R&D Systems.

## Data Acquisition and Statistics

Data were acquired on a BD Fortessa flow cytometer or BD LSRII flow cytometer (BD Biosciences) and were analyzed using FlowJo version 9.9.5 (FlowJo, LLC). Statistical analyses were performed using Prism version 7 (GraphPad Software).

## RESULTS

### V $\delta$ 2<sup>+</sup> $\gamma$ $\delta$ T Cells Can Be Activated by Cytokines in a TCR-Independent Manner

We sought to determine if distinct CD161 expression is linked to different cytokine responsiveness of V $\delta$ 2<sup>+</sup> and V $\delta$ 1<sup>+</sup> subsets of  $\gamma$  $\delta$ T cells, as these are the two most prominent subsets of  $\gamma$  $\delta$ T cells in the blood. V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cells and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells were both abundant in blood (mean of 1.2 and 1.9% of all CD3<sup>+</sup> T cells, respectively) (**Figure 1A**), with no significant difference in frequency compared to MAIT cells. V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells predominantly expressed CD161 (77%), compared to only 26% of V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cells ( $P < 0.001$ ; **Figure 1B**), in line with previous reports (15–17). There was significantly greater per-cell expression of CD161 [as measured by mean fluorescence intensity (MFI)] on the CD161<sup>+</sup> V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells compared to the CD161<sup>+</sup> V $\delta$ 1<sup>+</sup>  $\gamma$  $\delta$ T cell subset ( $P < 0.01$ ; **Figure 1C**). When compared to the MAIT cell population, a smaller fraction of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells expressed CD161 and had


**TABLE 1** | Characteristics of the hepatitis C virus (HCV) study cohort.

No.	Diagnosis	Sex	Age (years)	Viral load at analysis (IU/ml)	ALT (U/l)	Genotype
C01	Chronic HCV	F	45	3,329,040	151	1a
C02	Chronic HCV	M	62	nd	57	1a
C03	Chronic HCV	F	41	nd	32	1a
C04	Chronic HCV	F	53	nd	37	1b
C05	Chronic HCV	M	35	3,112,341	80	3a
C06	Chronic HCV	M	43	2,906,681	70	1a
C07	Chronic HCV	F	39	nd	30	1a
C08	Chronic HCV	M	43	nd	45	1a
C09	Chronic HCV	F	38	317,284	186	1a
C10	Chronic HCV	M	57	452,725	204	1a
C11	Chronic HCV	M	58	1,670,744	64	1b
C12	Chronic HCV	M	60	nd	86	3a
C13	Chronic HCV	M	57	nd	54	1b
C14	Chronic HCV	F	53	398,025	47	1b
C15	Chronic HCV	F	32	516,631	59	3a
C16	Chronic HCV	F	53	nd	36	3a
C17	Chronic HCV	F	20	1055,355	57	1b
C18	Chronic HCV	M	61	nd	92	1a
C19	Chronic HCV	F	39	3,394,892	61	1b
C20	Chronic HCV	M	35	8,336	206	1a
C21	Chronic HCV	F	51	2,897,088	70	1b
C22	Chronic HCV	M	42	nd	75	3a
C23	Chronic HCV	M	32	3,896,798	86	1b
C24	Chronic HCV	M	35	nd	189	3a
C25	Chronic HCV	F	32	nd	32	3a
C26	Chronic HCV	F	76	nd	21	1b
C27	Chronic HCV	F	49	26,121	32	3
C28	Chronic HCV	M	73	1,223,768	59	1b
C29	Chronic HCV	M	33	nd	104	1b
C30	Chronic HCV	M	52	499,162	120	3a
C31	Chronic HCV	M	48	nd	25	1b
C32	Chronic HCV	F	29	1,518,936	29	1a
C33	Chronic HCV	M	48	nd	26	2

reduced per-cell expression of CD161 ( $P < 0.001$ ; **Figures 1B,C**). Thus, based on CD161 expression, Vδ2+ γδT cells appeared more similar to MAIT cells than the Vδ1+ γδT cell population.

We next sought to determine if the production of IFN-γ by CD161+ γδT cells in response to TCR-independent cytokine stimulation occurred in both the Vδ1+ and Vδ2+ γδT cell subsets. Combinatorial stimulation with IL-12 + IL-18, IL-12 + IL-15, or IFN-β + IL-18 for 20 h was performed (**Figure 1D**), as these cytokine combinations have been previously shown to potently activate MAIT cells (2, 3). In response to cytokine stimulation, a large fraction of Vδ2+ γδT cells and MAIT cells produced IFN-γ, while production of IFN-γ by Vδ1+ γδT cells was negligible (**Figures 1D,E**). For all three stimuli, equivalent responses by Vδ2+ γδT cells and MAIT cells were observed. IL-12 + IL-18 and

IL-12 + IL-15 were the most potent stimuli (45% IFN-γ+ and 43% IFN-γ+ of Vδ2+ γδT cells, respectively), while IFN-β + IL-18 was the least stimulatory (15% IFN-γ+ of Vδ2+ γδT cells). Intriguingly, within the Vδ2+ γδT cell population, both CD161+ and CD161- cells produced IFN-γ in response to all three stimuli (**Figure 1F**). However, a significantly larger fraction of CD161+ Vδ2+ γδT cells produced IFN-γ than the CD161- subset ( $P < 0.05$ ; **Figure 1F**), consistent with a previous report of increased cytokine-responsiveness in the CD161+ γδT cell population (8). For IL-12 + IL-18 stimulation, the CD161+ Vδ2+ γδT cells produced significantly more IFN-γ than MAIT cells ( $P < 0.05$ ), but this difference was not observed following IL-12 + IL-15 or IFN-β + IL-18 stimulation. Despite very minor production of IFN-γ by Vδ1+ γδT cells in response to cytokine stimulation, there was a trend toward




modestly increased IFN-γ production by the CD161+ fraction (Figure 1F). The fraction of Vδ1+ and Vδ2+ γδT cells that express CD161 did not change following cytokine stimulation (data not shown), suggesting that the IFN-γ producing CD161- γδT cells do not represent downregulation of CD161 in response to stimulation. Overall, these data demonstrate that, akin to MAIT cells, the Vδ2+ γδT cell population has the inherent capacity to respond to cytokine stimulation. This corresponds to high expression of CD161 within this population, but cytokine responsiveness is an inherent trait seen in both the CD161+ and CD161- subsets.

### Vδ2+ γδT Cells Express Key Characteristics of Innate-Like T Cells

Expression of the transcription factor PLZF is a key positive regulator of innate-like T cell function and development (18–20). Given the central role of PLZF in promoting innate-like T cell functionality, we sought to characterize PLZF expression in Vδ2+ γδT cells. Analogous to MAIT cells, Vδ2+ γδT cells expressed

high levels of PLZF (Figures 2A,B), while PLZF expression was significantly lower on Vδ1+ γδT cells. When PLZF expression was assessed based on CD161 expression, both the CD161+ and CD161- subsets of Vδ2+ γδT cells expressed high levels of PLZF, but expression was significantly higher in the CD161+ subset (P < 0.01; Figure 2C). Despite low expression of PLZF in the Vδ1+ γδT cell population, there was still a trend toward increased expression in the CD161+ subset (Figure 2C).

We additionally examined the expression of IL-18Rα, as expression of this receptor can be regulated by PLZF (21, 22), and expression is necessarily related to responsiveness to IL-18-mediated activation. The vast majority (>95%) of Vδ2+ γδT cells expressed IL-18Rα, while only 31% of Vδ1+ γδT cells expressed IL-18Rα (P < 0.01; Figures 2A,D). Co-expression of IL-18Rα and PLZF was observed on Vδ2+ γδT cells and MAIT cells (Figure 2A), as expected. Similar to PLZF, both the CD161+ and CD161- subsets of Vδ2+ γδT cells expressed IL-18Rα at high levels, but again the CD161+ subset showed greater expression (P < 0.01; Figure 2E). Consistent with the inherent capacity of



Vδ2<sup>+</sup> γδT cells to respond to cytokine stimulation (**Figure 1**), the expression of PLZF and IL-18Rα is an inherent characteristic of these cells regardless of CD161 expression. However, CD161 expression correlated with increased expression of these molecules in line with the increased cytokine responsiveness, consistent with a previous report (8).


Intriguingly, in contrast to MAIT cells which exhibit negligible expression of Granzyme B in the steady state, approximately 40% of Vδ1<sup>+</sup> γδT cells and Vδ2<sup>+</sup> γδT cells expressed Granzyme B ( $P < 0.01$ ; **Figure 2F**). Expression of Granzyme B did not vary between the CD161<sup>+</sup> and CD161<sup>-</sup> subsets of either γδT cell population (**Figure 2G**). Thus, while Vδ2<sup>+</sup> γδT cells share phenotypic and transcriptional traits with MAIT cells, they do display differences with regard to baseline cytotoxic potential.

### Compared to MAIT Cells, Vδ2<sup>+</sup> γδT Cells Have a Reduced Capacity to Perform Type 17 Effector Functions

Mucosal-associated invariant T cells have the capacity to execute type 17 effector functions, in addition to standard

functionality of cytotoxic T lymphocytes (7, 23). Given the high degree of functional and phenotypic similarity observed thus far between Vδ2<sup>+</sup> γδT cells and MAIT cells, we sought to determine if Vδ2<sup>+</sup> γδT cells also had the capacity to produce IL-17A. As cytokine stimulation in the absence of TCR signaling does not induce IL-17A production by MAIT cells (data not shown), PMA + ionomycin stimulation was utilized. This stimulus led to IL-17A production by a small subset (mean of 2%) of MAIT cells (**Figures 3A,B**), in line with a previous report (23). However, IL-17A production by Vδ1<sup>+</sup> γδT cells and Vδ2<sup>+</sup> γδT cells was negligible (mean of 0.3% for both populations) and significantly lower than MAIT cell production ( $P < 0.01$ ; **Figures 3A,B**).


Given the lack of IL-17A production by Vδ2<sup>+</sup> γδT cells, we assessed the expression of the key transcriptional regulator of type 17 T cell functionality, RORγt. Consistent with the lack of IL-17A production by Vδ2<sup>+</sup> and Vδ1<sup>+</sup> γδT cells, both of these cell populations had significantly lower expression of RORγt as compared to MAIT cells ( $P < 0.01$ ; **Figure 3C**). While, RORγt MFI was modestly increased within the CD161<sup>+</sup> subset of Vδ2<sup>+</sup> γδT cells, it did not approach levels



seen in MAIT cells ( $P < 0.01$ ; **Figure 3D**). In line with the low expression of RORγt, only a very small fraction of Vδ1<sup>+</sup> and Vδ2<sup>+</sup> γδT cells expressed CCR6, and expression was not increased on the CD161<sup>+</sup> subsets (**Figures 3E,F**). While Vδ2<sup>+</sup> γδT cells share innate-like functionality with MAIT cells, the two populations do not share the capacity to execute type 17 effector functions.

### Human Intestinal and Hepatic Vδ2<sup>+</sup> γδT Cells Also Exhibit TCR-Independent Activation Potential


Mucosal-associated invariant T cells are present at a high frequency in human intestinal and liver tissues (24–27). Thus, we next sought to determine the frequency of Vδ2<sup>+</sup> γδT cells in these




tissues, and if these cells maintained their innate-like capacity within tissues. We first examined the frequency and functionality of cells extracted from human duodenal biopsies (Figure 4A). Vδ2+ γδT cells comprised on average 0.5% of all duodenal CD3+ T cells, and this represented a trend toward reduced frequency compared to blood ( $P = 0.06$ ; Figure 4B). No significant differences in frequency of Vδ1+ γδT cells and MAIT cells between blood and duodenum were observed. Consistent with blood, >80% of Vδ2+ γδT cells in the duodenum expressed CD161, while expression was significantly lower in the Vδ1+ γδT cell population ( $P < 0.01$ ; Figure 4C). Both MAIT cells and Vδ2+ γδT cells from the duodenum had greater expression of IL-18Rα than the Vδ1+ γδT cell population ( $P < 0.05$ ; Figure 4D). We next stimulated duodenum-derived mononuclear cells with IL-12 + IL-18. Analogous to blood-derived cells, the Vδ2+ γδT cell population responded robustly to this stimulus by producing IFN-γ ( $P = 0.7$ ; Figures 4E,F), while the Vδ1+ γδT cell population was minimally

responsive. The expression of CD161 on either the Vδ2+ or Vδ1+ γδT cells did not significantly affect production of IFN-γ in response to IL-12 + IL-18 stimulation, although a trend was observed ( $P \leq 0.1$ ; Figure 4G). Akin to blood, Vδ2+ γδT cells from the duodenum were activated by IL-12 + IL-18 stimulation regardless of expression of CD161.

We next examined the functionality of liver-derived γδT cells. Vδ1+ γδT cells, Vδ2+ γδT cells, and MAIT cells were abundant in human liver (mean of 4, 4, and 6% of CD3+ T cells for Vδ1+ γδT cells, Vδ2+ γδT cells, and MAIT cells, respectively; Figure 5A). In all other respects liver-derived Vδ2+ γδT cells appeared functionally and phenotypically equivalent to blood- and duodenum-derived cells. Liver Vδ2+ γδT cells expressed high levels of CD161 and IL-18Rα (Figures 5B,C). Furthermore, IL-12 + IL-18 stimulation resulted in robust IFN-γ production by Vδ2+ γδT cells, comparable to MAIT cells, and these responses were significantly larger than seen in Vδ1+ γδT cells ( $P < 0.05$ ;





**FIGURE 6** | Peripheral blood Vδ2<sup>+</sup> γδT cell frequency and cytokine-dependent function is maintained during chronic hepatitis C virus (cHCV) infection. **(A)** Frequency of Vδ1<sup>+</sup> γδT cells, Vδ2<sup>+</sup> γδT cells, and mucosal-associated invariant T (MAIT) cells as a fraction of all CD3<sup>+</sup> T cells in the blood of healthy donors and patients with cHCV. **(B,C)** Peripheral blood mononuclear cells were stimulated for 20 h with IL-12 and IL-18 **(B)**, or IL-12 and IL-15 **(C)** (50 ng/ml). Brefeldin A and Monensin were added for the final 4 h. Production of IFN-γ by each cell subset from healthy donors and HCV patients. **(D–F)** Expression of CD161 **(D)**, PLZF **(E)**, and Granzyme B **(F)** on Vδ1<sup>+</sup> γδT cells, Vδ2<sup>+</sup> γδT cells, and MAIT cells. Mean ± SEM. Symbols represent individual donors ( $N = 11–33$ ). \*\*\* $P < 0.001$ ; \*\* $P < 0.01$ ; \* $P < 0.05$ . **(A)**  $T$  test and **(B–F)** two-way ANOVA with Tukey's multiple comparison test.

**Figure 5D**). In sum, Vδ2<sup>+</sup> γδT cells derived from intestinal and liver tissues maintain their phenotype and responsiveness to cytokine stimulation.

## Vδ2<sup>+</sup> γδT Cell Frequency and Innate-Like Functionality Is Maintained During Chronic HCV Infection

It has been previously reported that MAIT cells can be activated *in vitro* and *in vivo* by HCV *via* cytokines, and that MAIT cells can inhibit HCV replication *in vitro* (3). Furthermore, chronic HCV infection has been shown to reduce the frequency of circulating and liver MAIT cells (3, 28–31), but no impairment in IFN-γ production in response to cytokine-mediated activation has been observed (28–31). Although several studies have examined alterations in frequency and functionality of γδT cells during chronic HCV infection (32–34), the phenotype and functionality of Vδ2<sup>+</sup> γδT cells has not been examined in detail. Thus, we sought to determine the impact of chronic HCV infection on the frequency and functionality of Vδ2<sup>+</sup> γδT cells. We utilized a cohort of chronically HCV-infected individuals (**Table 1**) and matched controls. Chronic HCV infection significantly reduced the frequency of circulating MAIT cells ( $P < 0.05$ ; **Figure 6A**). By contrast, the frequencies of Vδ1<sup>+</sup> γδT cells and Vδ2<sup>+</sup> γδT cells were unaffected by chronic HCV infection (**Figure 6A**). Vδ2<sup>+</sup> γδT cells from

chronically HCV-infected individuals also displayed unimpaired production of IFN-γ in response to IL-12 + IL-18 or IL-12 + IL-15 stimulation (**Figures 6B,C**). In healthy controls, Vδ2<sup>+</sup> γδT cells and MAIT cells responded equivalently to IL-12 + IL-18 stimulation (**Figure 6B**). By contrast, chronically HCV-infected patients showed increased responsiveness of Vδ2<sup>+</sup> γδT cells to IL-12 + IL-18 stimulation compared to MAIT cells (**Figure 6B**). However, this difference was not seen following IL-12 + IL-15 stimulation (**Figure 6C**). Consistent with the maintained functionality, Vδ2<sup>+</sup> γδT cells from chronically HCV-infected individuals expressed high levels of CD161, PLZF, and Granzyme B, equivalent to levels seen in Vδ2<sup>+</sup> γδT cells from healthy controls (**Figures 6D–F**). Vδ1<sup>+</sup> γδT cells, Vδ2<sup>+</sup> γδT cells, and MAIT cells from chronically HCV-infected patients maintained the differences in expression of CD161, PLZF, and Granzyme B that was observed in healthy controls. In sum, chronic HCV infection does not appear to impact on the frequency, phenotype, or innate-like functionality of Vδ2<sup>+</sup> γδT cells, thus highlighting a difference between Vδ2<sup>+</sup> γδT cells and MAIT cells.

## DISCUSSION

In the current study, we demonstrate that Vδ2<sup>+</sup> γδT cells are a major population of innate-like, cytokine-responsive T cells, which mirror MAIT cells with regard to frequency, phenotype,

and innate-like functionality. In line with previous studies (15–17), we have determined that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are the major population of CD161<sup>+</sup>  $\gamma$  $\delta$ T cells, and that the CD161<sup>+</sup> subset displays enhanced innate-like phenotype and functionality. Thus, we conclude that the prior report that CD161<sup>+</sup>  $\gamma$  $\delta$ T cells are a cytokine-responsive population (8), actually identifies the V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell population. Collectively, this study demonstrates the highly similar biology of human MAIT and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells with regard to TCR-independent, cytokine-driven activation. These data highlight the importance of examining both cell populations when considering cytokine-mediated activation of lymphocyte populations.

One area of particular interest with regard to cytokine-mediated activation is in the context of viral infections. While neither MAIT cells, whose TCRs recognize riboflavin-based metabolites in the context of MR1 (35), nor V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells, whose TCRs recognize phospho-antigens through Butyrophilin 3A1 (36, 37), can directly sense virus-derived antigens, both populations can be activated by viral infections *in vitro* (3, 6, 13). These studies also reported *in vivo* activation of MAIT cells in patients following influenza, dengue, or HCV infection (3, 6). Analysis of *in vivo* V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell activation was not performed. For all viral infections studied, both Type I IFNs and IL-18 were critical for the activation of these cell populations, thus highlighting the biologic relevance of this cytokine-mediated activation pathway. Using the most reductionist system of recombinant cytokines in the absence of ongoing viral infection, our data confirm the observation that cytokines can activate V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells to carry out effector functions. While the exact impact of virus-mediated activation of MAIT cells or V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells on disease outcomes remains to be determined, our data illustrate that both populations are equally responsive to this mechanism of activation. Thus, it is important for future studies examining the role of innate-like T cells in human viral infections to consider both MAIT and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells.

Toward this point, the impact of chronic HCV infection on MAIT cell frequency and function has been examined extensively, but the same is not true for the V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell population. MAIT cell frequencies decline in both the circulation and in the liver during HCV infection (3, 28–31). We observed no significant reduction in the frequency of circulating V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells in chronically HCV-infected patients, in contrast to a previous report (32). The reasons for the differences in reported frequency of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells between cohorts of HCV-infected patients remain unclear. However, our cohort had lower serum ALT levels ( $71.35 \pm 11.49$ ; **Table 1**) compared to the prior study ( $165.5 \pm 16$ ), which suggests that degree of tissue damage may impact on the frequency of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells during chronic HCV infection. However, it is clear that further investigation is required to better elucidate any interplay between HCV infection and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell frequency especially in the liver, the site of infection. We found that circulating V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells from HCV-infected patients displayed an unimpaired capacity to produce IFN- $\gamma$  in response to cytokine stimulation, and consistent with this, these cells maintained expression of PLZF. MAIT cells from chronically HCV-infected individuals, despite reduced frequencies, also maintained the capacity for cytokine-induced production of

IFN- $\gamma$  (**Figure 6**), consistent with prior reports (28–31). Thus, it appears that innate-like functionality can be maintained in the setting of chronic viral infection, despite reduced TCR-mediated functionality (28, 30). This characteristic makes both MAIT cells and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells attractive therapeutic targets, as both cells have been shown to be capable of inhibiting HCV replicons *in vitro* (3, 38).

While V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cell frequencies are differentially affected by chronic HCV infection, we report many shared characteristics between these two populations with regard to tissue distribution, innate-like phenotype, and responsiveness to cytokine stimulation. However, there are two key fundamental biologic traits where the functionalities of these cell populations diverge. First, V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells constitutively express Granzyme B (**Figure 2**) (39), but with large individual-to-individual variation in steady-state expression (40). By contrast, at rest, MAIT cells do not express Granzyme B (**Figure 2**) and instead must undergo licensing before expression occurs (41). While both populations can ultimately secrete fully loaded cytotoxic granules, these differences in steady-state composition may have important implications for the kinetics of the cytotoxic response from each population. Second, MAIT cells display a mixed Tc1/Th17 phenotype with the ability to produce IFN- $\gamma$  and cytotoxic granules, while also producing IL-17A and IL-22 (42). This correlates with high expression of the Th17-driving transcription factor ROR $\gamma$ t and Th17-associated markers such as CCR6 and IL-23R (7, 23). By contrast, in this comparative study, we could not detect type 17 immune functionality for V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells (**Figure 3**), and this corresponded to low expression of ROR $\gamma$ t and absence of CCR6. These data suggest that V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are minor innate-like type 17 effector cells compared to MAIT cells.

Detailed transcriptional comparisons of MAIT and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells will enhance our understanding of the regulatory networks and pathways involved in regulating innate-like T cells. It appears that the difference in type 17 functionality of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cells represents an example of different regulatory networks associated with the core innate-like T lymphocyte transcriptional program. Both innate-like T cell populations express PLZF to similar levels, but differ with regard to type 17 effector functionality. Intriguingly, it has been reported that PLZF regulates expression of ROR $\gamma$ t and thus type 17 effector functionality in a context-dependent manner. In particular, it has been reported on the one hand that PLZF can downregulate ROR $\gamma$ t (43), and on the other hand, it controls IL-17A-producing cord blood-derived  $\gamma$  $\delta$ T cell maturation (44). Thus, a better understanding of how PLZF might be differentially regulating gene expression in V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cells is of considerable interest.

Detailed transcriptional comparisons of MAIT and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells will also enhance our understanding of the true core factors and pathways involved in innate-like functionality of human T cells. We have previously reported such a “cytokine-responsive” transcriptional signature derived from human MAIT cells (8). Expression of CD161 was defined as a core marker of this transcriptional signature, but we now demonstrate that both CD161<sup>+</sup> and CD161<sup>-</sup> V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells robustly produce IFN- $\gamma$  in response to cytokine stimulation, albeit with enhanced responses

in the CD161<sup>+</sup> subset. With our increased understanding of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cell biology, hopefully this transcriptional signature can be further refined to identify core genes necessary for cytokine-dependent, TCR-independent activation of human T cells.

In conclusion, human V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cells represent two innate-like T cell populations with overlapping tissue distribution and responsiveness to cytokine-mediated activation. However, MAIT cells and V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells differ in their ability to execute type 17 effector functions and baseline cytotoxic granule composition. As a case study, we demonstrate that circulating V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells are maintained in frequency and functionality during chronic HCV infection, a disease where MAIT cell numbers decline (3, 28–31). In sum, this study not only links CD161 expression to the proficient cytokine responsiveness of V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells but also sheds light on the overlapping nature, accompanied by unique features, of innate-like T cells in the circulation and within tissues exemplified by V $\delta$ 2<sup>+</sup>  $\gamma$  $\delta$ T cells and MAIT cells. In particular, the differential impact of chronic HCV infection on these populations reveals the necessity for both innate-like T cell subsets to be considered in the complex immune interplay of a clinically relevant viral infection.

## ETHICS STATEMENT

Written informed consent was received from all subjects in accordance with the Declaration of Helsinki. Duodenal tissue, liver tissue, and matched blood samples were collected under a specific project approved under the study, “Gastrointestinal Illness in Oxford: prospective cohort for outcomes, treatment, predictors and biobanking” which in turn was approved by the relevant local research ethics committee (Ref: 11/YH/0020). Furthermore, blood samples from chronically HCV-infected patients or healthy blood donors and liver tissue were collected

## REFERENCES

- Franciszkiwicz K, Salou M, Legoux F, Zhou Q, Cui Y, Bessoles S, et al. MHC class I-related molecule, MR1, and mucosal-associated invariant T cells. *Immunol Rev* (2016) 272:120–38. doi:10.1111/imr.12423
- Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. CD161<sup>+</sup> CD8<sup>+</sup> T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. *Eur J Immunol* (2014) 44:195–203. doi:10.1002/eji.201343509
- van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, et al. MAIT cells are activated during human viral infections. *Nat Commun* (2016) 7:11653. doi:10.1038/ncomms11653
- Sattler A, Dang-Heine C, Reinke P, Babel N. IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions. *Eur J Immunol* (2015) 45:2286–98. doi:10.1002/eji.201445313
- Slichter CK, McDavid A, Miller HW, Finak G, Seymour BJ, McNeven JP, et al. Distinct activation thresholds of human conventional and innate-like memory T cells. *JCI Insight* (2016) 1:e86292. doi:10.1172/jci.insight.86292DS1
- Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. *Proc Natl Acad Sci U S A* (2016) 113:10133–8. doi:10.1073/pnas.1610750113
- Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8 $\alpha$ <sup>+</sup> semi-invariant T cells. *Blood* (2011) 118:2752–62. doi:10.1182/blood-2011-02-334698
- Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R, et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *CellReports* (2014) 9:1075–88. doi:10.1016/j.celrep.2014.09.045
- Kalyan S, Kabelitz D. Defining the nature of human  $\gamma$  $\delta$  T cells: a biographical sketch of the highly empathetic. *Cell Mol Immunol* (2012) 10:21–9. doi:10.1038/cmi.2012.44
- Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE, et al. Clonal selection in the human V $\delta$ 1 T cell repertoire indicates  $\gamma$  $\delta$  TCR-dependent adaptive immune surveillance. *Nat Commun* (2017) 8:14760. doi:10.1038/ncomms14760
- Casorati G, De Libero G, Lanzavecchia A, Migone N. Molecular analysis of human gamma/delta+ clones from thymus and peripheral blood. *J Exp Med* (1989) 170:1521–35. doi:10.1084/jem.170.5.1521
- Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. *J Exp Med* (1990) 171:1597–612. doi:10.1084/jem.171.5.1597
- Tsai C-Y, Liong KH, Gunalan MG, Li N, Lim DSL, Fisher DA, et al. Type I IFNs and IL-18 regulate the antiviral response of primary human  $\gamma$  $\delta$  T cells against dendritic cells infected with Dengue virus. *J Immunol* (2015) 194:3890–900. doi:10.4049/jimmunol.1303343
- Skeen MJ, Ziegler HK. Activation of gamma delta T cells for production of IFN-gamma is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. *J Immunol* (1995) 154:5832–41.
- Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G, et al. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. *J Immunol* (1997) 159:3723–30.

through the “Hepatologische Biobank des Universitaetsklinikums Freiburg” (HBUF; 474/14) under the specific project Ref: 275/15 approved by the local ethics committee. Peripheral bloods were also acquired from anonymized healthy blood donors through the NHS Blood and Transplant Service.

## AUTHOR CONTRIBUTIONS

NP, MF, BB, and AS performed experiments. KW and LG prepared and provided samples. NP, MF, BB, AS, BW, RT, MH, and PK designed the experiments. All authors contributed to the writing and editing of the manuscript.

## ACKNOWLEDGMENTS

We would like to thank James Chivenga and Cloe Vassart for assistance with consenting patients (Oxford GI Biobank). We would also like to thank Helen Ferry of the NDM Flow Cytometry Facility (University of Oxford) for technical assistance. We would like to thank Catrin Tauber for her help with tissue sampling.

## FUNDING

NP is funded by an Oxford-UCB Postdoctoral Fellowship. MF is supported by an Oxford-Celgene Doctoral Fellowship. KW and LG are supported by the Wellcome Trust PhD Studentship (KDW, [200154/Z/15/Z]; LG, [109028/Z/15/Z]). PK is supported by the Wellcome Trust ([WT109965MA]); the Medical Research Council (STOP-HCV); an NIHR Senior Fellowship; and the NIHR Biomedical Research Centre (Oxford). BB was funded by MOTI-VATE (Else-Kröner-Fresenius-Stiftung). AS, MH, and RT are supported by SFB/TRR179 and SFB1160 [German Research Foundation (DFG)].

16. Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, et al. IL-12-mediated NKR1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. *J Immunol* (1999) 162:4349–54.
17. Poggi A, Zocchi MR, Carosio R, Ferrero E, Angelini DE, Galgani S, et al. Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. *J Immunol* (2002) 168:6071–7. doi:10.4049/jimmunol.168.12.6071
18. Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SBG, Meehan B, et al. Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. *J Exp Med* (2015) 212:1095–108. doi:10.1038/nprot.2007.315
19. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. *Immunity* (2008) 29:391–403. doi:10.1016/j.immuni.2008.07.011
20. Koay H-F, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. *Nat Immunol* (2016) 17:1300–11. doi:10.1038/ni.3565
21. Mao A-P, Constantinides MG, Mathew R, Zuo Z, Chen X, Weirauch MT, et al. Multiple layers of transcriptional regulation by PLZF in NKT-cell development. *Proc Natl Acad Sci U S A* (2016) 113:7602–7. doi:10.1073/pnas.1601504113
22. Gleimer M, Boehmer von H, Kreslavsky T. PLZF controls the expression of a limited number of genes essential for NKT cell function. *Front Immunol* (2012) 3:374. doi:10.3389/fimmu.2012.00374
23. Billerbeck E, Kang Y-H, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. *Proc Natl Acad Sci U S A* (2010) 107:3006–11. doi:10.1073/pnas.0914839107
24. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* (2003) 422:164–9. doi:10.1038/nature01433
25. Jeffery HC, van Wilgenburg B, Kurioka A, Parekh K, Stirling K, Roberts S, et al. Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. *J Hepatol* (2016) 64:1118–27. doi:10.1016/j.jhep.2015.12.017
26. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. *J Exp Med* (2013) 210:2305–20. doi:10.1084/jem.20130958
27. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. *J Immunol* (2013) 190:3142–52. doi:10.4049/jimmunol.1203218
28. Hengst J, Strunz B, Deterding K, Ljunggren H-G, Leeansyah E, Manns MP, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. *Eur J Immunol* (2016) 46:2204–10. doi:10.1002/eji.201646447
29. Spaan M, Hulleger SJ, Beudeker BJB, Kreeft K, van Oord GW, Groothuisink ZMA, et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. *PLoS One* (2016) 11:e159243–159213. doi:10.1371/journal.pone.0159243
30. Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, et al. Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation. *Gastroenterology* (2017) 153:1392.e–403.e. doi:10.1053/j.gastro.2017.07.043
31. Beudeker BJB, van Oord GW, Arends JE, Schulze zur Wiesch J, van der Heide MS, de Knegt RJ, et al. Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis. *Liver Int* (2017) 388:1081–1011. doi:10.1111/liv.13544
32. Pár G, Rukavina D, Podack ER, Horányi M, Szekeres-Barthó J, Hegedüs G, et al. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 Tcr+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. *J Hepatol* (2002) 37:514–22. doi:10.1016/S0168-8278(02)00218-0
33. Tseng CT, Miskovsky E, Houghton M, Klimpel GR. Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. *Hepatology* (2001) 33:1312–20. doi:10.1053/jhep.2001.24269
34. Agrati C, D'Offizi G, Narciso P, Abrignani S, Ippolito G, Colizzi V, et al. Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons. *Mol Med* (2001) 7:11–9.
35. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* (2012) 491:717–23. doi:10.1038/nature11605
36. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, Daker El S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human  $\gamma$  $\delta$  T cells. *Nat Immunol* (2013) 14:908–16. doi:10.1038/ni.2665
37. Sandstrom A, Peigné C-M, Léger A, Crooks JE, Konczak F, Gesnel M-C, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V $\gamma$ 9V $\delta$ 2 T cells. *Immunity* (2014) 40:490–500. doi:10.1016/j.immuni.2014.03.003
38. Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR, et al. Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. *Int Immunol* (2006) 18:11–8. doi:10.1093/intimm/dxh337
39. Pont F, Familiades J, Déjean S, Fruchon S, Cendron D, Poupot M, et al. The gene expression profile of phosphoantigen-specific human  $\gamma$  $\delta$ T lymphocytes is a blend of  $\alpha$  $\beta$  T-cell and NK-cell signatures. *Eur J Immunol* (2011) 42:228–40. doi:10.1002/eji.201141870
40. Ryan PL, Sumaria N, Holland CJ, Bradford CM, Izotova N, Grandjean CL, et al. Heterogeneous yet stable V $\delta$ 2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. *Proc Natl Acad Sci U S A* (2016) 113:14378–83. doi:10.1073/pnas.1611098113
41. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. *Mucosal Immunol* (2015) 8:429–40. doi:10.1038/mi.2014.81
42. Kurioka A, Walker LJ, Klenerman P, Willberg CB. MAIT cells: new guardians of the liver. *Clin Transl Immunology* (2016) 5:e98. doi:10.1038/cti.2016.51
43. Muñoz-Ruiz M, Sumaria N, Pennington DJ, Silva-Santos B. Thymic determinants of gd T cell differentiation. *Trends Immunol* (2017) 38:336–44. doi:10.1016/j.it.2017.01.007
44. Lu Y, Cao X, Zhang X, Kovalovsky D. PLZF controls the development of fetal-derived IL-17 +V $\gamma$ 6 + $\gamma$  $\delta$  T cells. *J Immunol* (2015) 195:4273–81. doi:10.4049/jimmunol.1500939

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Provine, Binder, FitzPatrick, Schuch, Garner, Williamson, van Wilgenburg, Thimme, Klenerman and Hofmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.